Why the study?
Does periprocedural anticoagulation therapy with rivaroxaban improve safety in Japanese patients undergoing catheter ablation of paroxysmal NVAF?
Does periprocedural anticoagulation therapy with rivaroxaban improve safety in Japanese patients undergoing catheter ablation of paroxysmal NVAF?
Periprocedural anticoagulation with rivaroxaban appears safe and feasible in Japanese patients undergoing catheter ablation for paroxysmal NVAF.
Answers are grounded in this paper and cite their sources.
Supports periprocedural rivaroxaban safety in Japanese paroxysmal NVAF ablation; hypothesis-generating, requires randomized confirmation.
-VASc score were 1.2 ± 1.0 and 0.6 ± 0.7, respectively. Their mean HAS-BLED score was 1.0 ± 0.8. Neither major bleeding nor thromboembolic events, except in a case with bleeding from gastric cancer (1.4%), were observed in the periprocedural period of the AF ablation.The present multicenter study demonstrated the safety and feasibility of periprocedural anticoagulation therapy with rivaroxaban in Japanese patients undergoing catheter ablation of paroxysmal NVAF.
No takes yet. Share an insight, caveat, or question.
Kawabata et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: